UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
_____________________________ 
FORM 8-K
  _____________________________ 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 20, 2018
  _____________________________ 
Medtronic Public Limited Company
(Exact name of Registrant as Specified in its Charter)
   _____________________________ 
 
Ireland
 
1-36820
 
98-1183488
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
 
                
20 On Hatch, Lower Hatch Street
Dublin 2, Ireland
(Address of principal executive offices)
(Registrant’s telephone number, including area code): +353 1 438-1700
  _____________________________ 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o







Item 2.02.
Results of Operations and Financial Condition

On November 20, 2018, Medtronic plc, a public limited company organized under the laws of Ireland, issued a press release announcing its second quarter fiscal year 2019 financial results. A copy of the press release is furnished as Exhibit 99.1 to this report.
 
Item 9.01.
      Exhibits.
(d) List of Exhibits
Exhibit Number
  
Description
 
 
99.1
  
Press release of Medtronic plc, dated November 20, 2018










SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MEDTRONIC PUBLIC LIMITED COMPANY
 
 
 
 
 
 
 
 
By
 
/s/ Karen L. Parkhill
Date: November 20, 2018
 
 
 
 
 
Karen L. Parkhill
 
 
 
 
 
 
Executive Vice President and Chief Financial Officer









EXHIBIT INDEX

Exhibit Number
  
Description
 
 
  
Press release of Medtronic plc, dated November 20, 2018





Medtronic (NYSE:MDT)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Medtronic Charts.
Medtronic (NYSE:MDT)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Medtronic Charts.